Calypte Biomedical Corp. (ticker: CALY, exchange: OTC Bulletin Board) News Release - 24-Sep-2003
--------------------------------------------------
Calypte Biomedical to Test its Urine Based HIV-1 Test in Tanzania, Rwanda, Burundi and Botswana
ALAMEDA, Calif., Sep 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test announced today that the company conducted meetings at the 13th International Conference on AIDS and Sexually Transmitted Infections (ICASA) being held in Nairobi, Kenya. These meetings allowed Calypte to present the case for urine HIV-1 testing before the top officials in Africa. Calypte's Urine based HIV-1 testing is FDA approved and is in growing demand in Africa.
Based on these meetings and previous discussions with individual government officials, Calypte Biomedical will initiate testing in Tanzania, Rwanda, Burundi, and Botswana.
Many countries want to move forward as quickly as possible on testing of the urine based product. With October funding proposals due, many countries have expressed the desire to utilize these funds for Calypte's urine based HIV-1 antibody tests.
Tony Cataldo, Calypte's Executive Chairman commented, "The momentum for international acceptance of Calypte's products has grown dramatically over the past several months and we anticipate that trend to continue. We believe that along with our recent funding and Calypte's experienced management team we are in a position to meet the increasing demand for our urine based HIV antibody tests."
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
SOURCE Calypte Biomedical Corporation
Investor Relations - Tim Clemensen of Rubenstein Communications
for Calypte Biomedical Corporation, +1-212-843-9337,
tclemensen@rubensteinir.com
|
Thread abonnieren
